Novavax shares fall as much as 32% after releasing early trial data on coronavirus vaccine – CNBC
Business News
- Novavax shares fall as much as 32% after releasing early trial data on coronavirus vaccine CNBC
- Novavax reports results of an early-stage Covid-19 trial data CNBC Television
- Novavax’s New Covid-19 Vaccine Studies Praised By Scientists The New York Times
- Novavax’s Covid-19 vaccine shows promising immune response STAT
- Novavax Covid-19 Vaccine Produces Positive Results in First-Stage Study The Wall Street Journal
- View Full Coverage on Google News
Source: Business News